CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

CAR T-Cell Therapy Continues to Generate Positive Results in Hematologic Cancers

January 29th 2020

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11th 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

CAR T-Cell Therapy as an Outpatient Treatment Option

December 23rd 2019

Anticipation of ZUMA-7 Results

December 23rd 2019

Next-Generation CAR T Therapy

December 23rd 2019

Expanded Use of CAR T Therapy in Hematologic Malignancies

December 23rd 2019

The TRANSCEND-NHL-001 Trial

December 23rd 2019

CAR T Associated Cytokine Release Syndrome

December 23rd 2019

Real-World Data and CAR T Therapy

December 23rd 2019

CAR-T Therapy Treatment Variables

December 23rd 2019

High-Risk Lymphoma: The ZUMA-1 and SCHOLAR-1 Trials

December 23rd 2019

Adult ALL and Data from ZUMA-3

December 23rd 2019

CAR T-Cell Therapy: Relapsed/Refractory ALL

December 23rd 2019

Treating Common Toxicities From CAR T Therapy

December 23rd 2019

A Conversation on MRD in ALL

December 23rd 2019

CAR T-Cell Therapy in Pediatric ALL

December 23rd 2019

Understanding of MRD and CAR T-Cell Therapy in ALL Continues to Evolve

December 23rd 2019

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL

December 22nd 2019

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

Real-World Analysis Shows Cost-Reducing Benefit With CAR-T in Relapsed DLBCL

December 20th 2019

Karl M. Kilgore, PhD, discusses how results of real-world analysis may impact the utilization of CAR T-cell therapy for older patients with relapsed/refractory diffuse large B-cell lymphoma.